Related Experiment Video
Updated: May 29, 2026

Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality
Published on: April 7, 2023
Characterization of enterococcus strains contained in probiotic products
Norihisa Noguchi1, Hidemasa Nakaminami, Keisuke Nakase
1Department of Microbiology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan. noguchin@toyaku.ac.jp
Abstract:
Probiotics are additives containing live microbes that beneficially affect a host by improving the properties of the host intestinal microflora. Recently, advances in medical treatments have led to increased numbers of immunocompromised patients; some patients contract opportunistic infections of Enterococcus species, which are considered non-pathogenic bacteria. To evaluate the safety of probiotics containing Enterococcus strains, we isolated Enterococcus from six probiotic products and compared the pathogenic genes and antimicrobial susceptibility of the probiotic strains to those of clinical isolates. Our study showed that all Enterococcus strains contained in probiotic products were E. faecium, and no vancomycin-resistant strains were found. In addition, no pathogenic genes, such as ace, agg, gelE, cylM, cylB, cylA, cpd, cob, ccf, efaA(fs), efaA(fm), esp(fs), or esp(fm), were found in the probiotic strains. Pulsed-field gel electrophoresis (PFGE) analysis showed obvious genetic differences between the probiotic strains and the clinical isolates. The data suggested that the probiotic Enterococcus strains were not transmitted to hospitalized patients. Therefore, our results strongly suggest that probiotic products are unlikely agents for causing opportunistic infections.
Insights
Probiotic products containing Enterococcus faecium strains are safe and do not cause opportunistic infections in immunocompromised patients. Genetic analysis confirmed these strains differ from clinical isolates, indicating no transmission risk.
Area of Science:
- Microbiology
- Probiotics
- Infectious Diseases
Background:
- Probiotics, live microbial additives, offer health benefits by modulating gut microflora.
- Increased immunocompromised populations raise concerns about opportunistic infections from normally non-pathogenic bacteria like Enterococcus species.
Purpose of the Study:
- To assess the safety of Enterococcus strains in probiotic products.
- To compare the pathogenic potential and genetic profiles of probiotic Enterococcus strains with clinical isolates.
Main Methods:
- Isolation of Enterococcus from six probiotic products.
- Analysis of pathogenic genes (e.g., ace, agg, esp) and antimicrobial susceptibility.
- Pulsed-field gel electrophoresis (PFGE) for genetic profiling.
Main Results:
- All probiotic strains identified as Enterococcus faecium (E. faecium).
- No vancomycin resistance or specific pathogenic genes were detected in probiotic strains.
- PFGE revealed significant genetic distinctions between probiotic and clinical Enterococcus isolates.
Conclusions:
- Probiotic E. faecium strains lack key virulence factors and genetic similarity to clinical strains.
- The study suggests probiotic products are unlikely to be a source of opportunistic Enterococcus infections.
Related Concept Videos
Probiotics
Bacterial Gastroenteritis
Microbes in the Production of Fermented Foods
Microbiota of the Large Intestine
Microbiota Modulation by Antibiotics
Microbiota of the Stomach and Small Intestine

